Literature DB >> 8954611

HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.

S Kooi1, H Z Zhang, R Patenia, C L Edwards, C D Platsoucas, R S Freedman.   

Abstract

This study was carried out to determine whether HLA class I or class II expression on ovarian tumor cells and lymphocytic infiltration of the epithelial ovarian carcinoma (EOC) tissues were responsible for the ability to expand tumor-infiltrating lymphocytes (TIL) in vitro in low concentrations of recombinant interleukin-2 (rIL-2). Immunohistochemical analysis was performed using monoclonal antibodies that recognize framework determinants of either HLA class I or HLA class II or leukocyte differentiation antigens (LCA, CD3, CD4, and CD8). Cryostat sections of EOC had HLA class I and HLA class II expression on at least 5% of tumor cells in 18 of 20 specimens (90%). From another portion of the same tumor specimens T-cell lines were developed from TIL in low concentrations of rIL-2 (200-600 IU/ml) in 7 of 17 patients. Tumors from which TIL were expanded in vitro with rIL-2 had significantly higher proportions of HLA class I-positive tumor cells (73 +/- 10%) compared to tumors from which TIL failed to grow (40 +/- 10%) (P = 0.036). However, there was no difference in the proportions of HLA class II-positive tumor cells between the two groups. Tumor specimens of patients whose TIL were expanded in rIL-2 had significantly higher numbers per field (423 +/- 114 vs 154 +/- 20; P = 0.005) and proportions (90 +/- 3% vs 77 +/- 4%; P = 0.023) of infiltrating CD3+ cells, significantly higher numbers per field (115 +/- 44 vs 19 +/- 5; P = 0.003) and proportions (25 +/- 5% vs 11 +/- 2%; P = 0.017) of CD8+ cells and significantly higher numbers per field of CD4+ cells (318 +/- 101 vs 113 +/- 18; P = 0.025), in comparison to tumor specimens from patients whose TIL did not grow in vitro. Significant correlations were observed between the proportions of HLA class I-positive EOC tumor cells and the numbers of infiltrating LCA-positive cells (r = 0.67; P = 0.005) CD3+ cells (r = 0.70; P = 0.002), CD4+ cells (r = 0.69; P = 0.003), and CD8+ cells (r = 0.82; P = 0.001). The proportions of HLA class II-positive tumor cells correlated positively (r = 0.45; P = 0.049) only with the numbers of CD8+-infiltrating cells. In conclusion, we report here that HLA class I expression on EOC cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro, in low concentrations of rIL-2.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8954611     DOI: 10.1006/cimm.1996.0301

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  23 in total

1.  Aneurysmal lesions of patients with abdominal aortic aneurysm contain clonally expanded T cells.

Authors:  Song Lu; John V White; Wan Lu Lin; Xiaoying Zhang; Charalambos Solomides; Kyle Evans; Nectaria Ntaoula; Ifeyinwa Nwaneshiudu; John Gaughan; Dimitri S Monos; Emilia L Oleszak; Chris D Platsoucas
Journal:  J Immunol       Date:  2014-04-21       Impact factor: 5.422

Review 2.  Tumor infiltrating lymphocytes in ovarian cancer.

Authors:  Phillip P Santoiemma; Daniel J Powell
Journal:  Cancer Biol Ther       Date:  2015-04-20       Impact factor: 4.742

3.  Association of CD8+ T cell infiltration in oesophageal carcinoma lesions with human leucocyte antigen (HLA) class I antigen expression and survival.

Authors:  T Tsuchikawa; H Ikeda; Y Cho; M Miyamoto; T Shichinohe; S Hirano; S Kondo
Journal:  Clin Exp Immunol       Date:  2011-02-24       Impact factor: 4.330

4.  T cell density and location can influence the prognosis of ovarian cancer.

Authors:  Ahmad Al-Attar; Mohamed Shehata; Lindy Durrant; Paul Moseley; Suha Deen; Stephen Chan
Journal:  Pathol Oncol Res       Date:  2009-12-19       Impact factor: 3.201

Review 5.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

Review 6.  Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.

Authors:  Masaki Mandai; Junzo Hamanishi; Kaoru Abiko; Noriomi Matsumura; Tsukasa Baba; Ikuo Konishi
Journal:  Int J Clin Oncol       Date:  2016-03-11       Impact factor: 3.402

Review 7.  The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

Authors:  Lana E Kandalaft; Nathan Singh; John B Liao; Andrea Facciabene; Jonathan S Berek; Daniel J Powell; George Coukos
Journal:  Gynecol Oncol       Date:  2009-12-02       Impact factor: 5.482

8.  Monocyte and interferon based therapy for the treatment of ovarian cancer.

Authors:  Daniel S Green; Ana T Nunes; Christina M Annunziata; Kathryn C Zoon
Journal:  Cytokine Growth Factor Rev       Date:  2016-03-15       Impact factor: 7.638

9.  Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines.

Authors:  M A Nash; R Lenzi; C L Edwards; J J Kavanagh; A P Kudelka; C F Verschraegen; C D Platsoucas; R S Freedman
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

10.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.